Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®
NCT ID: NCT00658099
Last Updated: 2017-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
699 participants
OBSERVATIONAL
2007-11-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes
NCT00715351
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
NCT01542489
Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment
NCT00865397
Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
NCT00806897
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
NCT00697450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
insulin detemir
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
B
insulin NPH
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
insulin detemir
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
insulin NPH
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c greater than 7.0% and/or hypoglycaemia
* variable FBG and/or weight increase
* the selection of the subjects will be at the discretion of the participating physician
Exclusion Criteria
* current treatment with Levemir® or Insulatard®
* hypersensitivity to Levemir® or Insulatard® or to any of the excipients
* women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Bucharest, , Romania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Doina Catrinoiu; Effect of Once-Daily Detemir vs NPH Insulin on Body Weight and Metabolic Control When Added to OADs in Type 2 Diabetes; 2029-PO; 69th Scientific Sessions (2009); American Diabetes Association
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN304-1976
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.